[Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017)].
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2017 May 14;38(5):364-370. doi: 10.3760/cma.j.issn.0253-2727.2017.05.002.
Abstract
摘要
相似文献
1
[Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017)].
Zhonghua Xue Ye Xue Za Zhi. 2017 May 14;38(5):364-370. doi: 10.3760/cma.j.issn.0253-2727.2017.05.002.
2
[Chinese guidelines on the treatment of hemophilia (version 2020)].
Zhonghua Xue Ye Xue Za Zhi. 2020 Apr 14;41(4):265-271. doi: 10.3760/cma.j.issn.0253-2727.2020.04.001.
3
[Chinese expert consensus on the diagnosis and treatment of acquired hemophilia A].
Zhonghua Xue Ye Xue Za Zhi. 2014 Jun;35(6):575-6. doi: 10.3760/cma.j.issn.0253-2727.2014.06.026.
4
[The RFLPs of St14/Taq I in Chinese and its application to gene analysis and prenatal diagnosis of hemophilia A].
Yi Chuan Xue Bao. 1989;16(4):325-30.
5
[Consensus of Chinese experts on diagnosis and treatment of hemophilia].
Zhonghua Xue Ye Xue Za Zhi. 2011 Mar;32(3):212-3.
6
Molecular diagnosis of hemophilia A in Chinese patients by an analysis of inversions in the factor VIII gene.
Hematopathol Mol Hematol. 1996;10(1-2):63-7.
7
[Similarities and differences in diagnosis and treatment of gastrointestinal stromal tumors between China, Japan and Korea: from expert consensus to cooperation prospect].
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Sep 25;22(9):812-819. doi: 10.3760/cma.j.issn.1671-0274.2019.09.003.
8
Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban China.
Health Qual Life Outcomes. 2012 Sep 15;10:112. doi: 10.1186/1477-7525-10-112.
9
[Chinese expert consensus on BRCA1/2 variant interpretation(2021 version)].
Zhonghua Bing Li Xue Za Zhi. 2021 Jun 8;50(6):565-571. doi: 10.3760/cma.j.cn112151-20201027-00809.
10
Classical hemophilia in a Filipino.
Acta Med Philipp. 1960 Jan-Mar;16:157-67.
引用本文的文献
1
Analysis of the current situation and influencing factors of home treatment for children with hemophilia in China.
Ann Hematol. 2025 Aug 15. doi: 10.1007/s00277-025-06552-2.
2
Assessing the health-state utility values of rare disease-hemophilia B using EQ-5D-5L: a study based on the Chinese population.
Orphanet J Rare Dis. 2025 Aug 7;20(1):407. doi: 10.1186/s13023-025-03894-y.
3
The effect of prophylactic FVIII infusion combined with personalized rehabilitation on joint health and quality of life in children with hemophilia.
Front Pediatr. 2025 Jul 10;13:1578617. doi: 10.3389/fped.2025.1578617. eCollection 2025.
4
Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.
Adv Ther. 2025 Jun 4. doi: 10.1007/s12325-025-03151-5.
5
Analysis of the current status and characteristics of osteoporosis in adult hemophilia patients based on high-resolution peripheral quantitative computed tomography: a case control study.
BMC Musculoskelet Disord. 2025 Mar 11;26(1):242. doi: 10.1186/s12891-025-08473-7.
6
Sequential combined bypassing therapy in haemophilia patients with high titer inhibitors: surgical experience.
Ann Hematol. 2025 Mar;104(3):1949-1960. doi: 10.1007/s00277-025-06265-6. Epub 2025 Feb 26.
7
Clinical analysis and quality of life survey of hemophilia B patients in the central and western regions of China.
Front Pediatr. 2024 May 9;12:1366990. doi: 10.3389/fped.2024.1366990. eCollection 2024.
8
Current status of treatment and disease burden of a cohort of hemophilia B in China.
Front Public Health. 2024 Jan 24;11:1303787. doi: 10.3389/fpubh.2023.1303787. eCollection 2023.
9
[Expert recommendations on homogenization management of the diagnosis and treatment of rare diseases in children].
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Jul 15;25(7):663-671. doi: 10.7499/j.issn.1008-8830.2304036.
10
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
BMC Med Res Methodol. 2022 Aug 5;22(1):215. doi: 10.1186/s12874-022-01659-w.
本文引用的文献
1
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437.
2
When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH.
J Thromb Haemost. 2016 May;14(5):1105-9. doi: 10.1111/jth.13298. Epub 2016 Apr 4.
3
Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.
J Thromb Haemost. 2016 Jul;14(7):1330-6. doi: 10.1111/jth.13356. Epub 2016 Jun 22.
4
Low-dose prophylaxis for severe haemophilia: a little goes a long way.
Haemophilia. 2016 May;22(3):331-3. doi: 10.1111/hae.12853. Epub 2015 Nov 27.
5
Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
Blood Coagul Fibrinolysis. 2016 Mar;27(2):136-40. doi: 10.1097/MBC.0000000000000389.
6
Individualizing prophylaxis in hemophilia: a review.
Expert Rev Hematol. 2015 Apr;8(2):237-46. doi: 10.1586/17474086.2015.1002465. Epub 2015 Jan 20.
7
Toward optimal therapy for inhibitors in hemophilia.
Blood. 2014 Nov 27;124(23):3365-72. doi: 10.1182/blood-2014-05-577643.
8
Validation of the Chinese version of the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool (the CHO-KLAT).
Haemophilia. 2014 Nov;20(6):794-9. doi: 10.1111/hae.12489. Epub 2014 Oct 2.
9
Definitions in hemophilia: communication from the SSC of the ISTH.
J Thromb Haemost. 2014 Nov;12(11):1935-9. doi: 10.1111/jth.12672. Epub 2014 Sep 3.
10
[Ultrasonographic characteristics of haemophilic arthropathy in the knee joints].
Zhonghua Xue Ye Xue Za Zhi. 2014 May;35(5):434-7. doi: 10.3760/cma.j.issn.0253-2727.2014.05.012.
Zotero 插件